Printer Friendly

Syros Presents New Preclinical Data on SY-1365 and SY-5609 at AACR Annual Meeting.

M2 PHARMA-April 8, 2019-Syros Presents New Preclinical Data on SY-1365 and SY-5609 at AACR Annual Meeting

(C)2019 M2 COMMUNICATIONS

- US-based gene control medicines developer Syros Pharmaceuticals (NASDAQ: SYRS) presented new preclinical data across its franchise of selective cyclin-dependent kinase 7 inhibitors at the American Association for Cancer Research annual meeting in Atlanta, the company said.

New data on SY-1365, a first-in-class selective CDK7 inhibitor currently in a Phase 1 clinical trial, suggest that RB pathway alterations are predictive of response in preclinical models of high-grade ovarian cancer and support the ongoing clinical investigation of SY-1365 in patient populations enriched for RB pathway alterations.

New preclinical data on SY-5609, a selective oral CDK7 inhibitor, demonstrate broad anti-tumor activity in preclinical models of triple-negative breast cancer and ovarian cancer.

Researchers from Syros evaluated tumor growth inhibition in a panel of HGOC patient derived xenograft models, including both high-grade serous ovarian cancer (HGSOC) and clear cell ovarian cancer, to determine whether RB pathway alterations predict response to treatment with SY-1365.

RB pathway alterations are present in 67% of HGSOC patients, according to The Cancer Genome Atlas analysis.

In Syros' study, RB pathway alterations were prospectively defined per The Cancer Genome Atlas criteria including RB1 deletion or mutation, CDKN2A downregulation or deletion, CCNE1 amplification, CCND1 amplification, or CCND2 upregulation.

These data show that ninety percent (9 of 10) of the PDX models with RB pathway alterations responded to treatment with SY-1365.

Forty percent (6 of 15) of the PDX models without prospectively defined RB alterations responded to treatment with SY-1365, suggesting the presence of other undetected RB pathway changes or alternative mechanisms, including transcriptional regulation, conferring sensitivity to SY-1365.

Overall, Syros believes these results support the ongoing development of SY-1365 in patient populations, including HGSOC and CDK4/6-inhibitor resistant hormone receptor-positive breast cancer, that are enriched for RB pathway alterations, as well as the evaluation of these alterations as potential biomarkers of response to SY-1365.

Syros is currently conducting a Phase 1 clinical trial assessing the safety and efficacy of SY-1365 as a single agent and in combination with standard-of-care therapies in multiple ovarian and breast cancer patient populations.

The trial includes cohorts evaluating SY-1365 as a single agent in patients with relapsed ovarian clear cell cancer; as a single agent in HGSOC patients who have had three or more prior lines of therapy; in combination with carboplatin in HGSOC patients who have had one or more prior lines of therapy; in combination with fulvestrant in HR+ breast cancer patients who are resistant to treatment with a CDK4/6 inhibitor; and as a single agent in patients with solid tumors accessible for biopsy.

Syros expects to report initial clinical data from the dose expansion portion of the trial in 4Q19.

SY-5609 Demonstrates Selectivity, Potency and Anti-Tumor Activity Preclinically

Researchers from Syros conducted a series of preclinical studies to characterise the in vitro and in vivo profile of SY-5609. The data show that SY-5609:

Demonstrated 13,000- to 49,000-fold greater selectivity for CDK7 over other CDK family members, including CDK2, CDK9 and CDK12.

Induced robust tumor growth inhibition effects and cell cycle arrest in TNBC and ovarian cancer cell lines at low nanomolar drug concentrations, with apoptosis demonstrated only in the TNBC and ovarian cancer models, but not in non-cancerous cells.

Significantly impacted tumor growth in vivo, with complete regressions observed with SY-5609 as a monotherapy in multiple TNBC and ovarian cancer cell line xenograft models at doses below the maximum tolerated dose.

Demonstrated substantial tumor growth inhibition in multiple TNBC and ovarian cancer PDX models, with minimum weight loss observed.

Led to decreases in CDK7 downstream protein markers, including MCL1, in treated tumor tissue, confirming CDK7 inhibition in vivo.

Syros is currently advancing SY-5609 through investigational new drug application enabling studies, with a Phase 1 oncology trial expected to begin in early 2020.

Syros is advancing medicines that control the expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA to identify and drug novel targets linked to genomically defined patient populations.

Because gene expression is fundamental to the function of all cells, Syros' gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases.

Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines.

Syros' lead drug candidates are SY-1425, a selective RAR? agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial focused on patients with ovarian and breast cancers.

The company is also developing a deep preclinical and discovery pipeline, including SY-5609, an oral CDK7 inhibitor, as well as programs in immuno-oncology and sickle cell disease. Led by a team with deep experience in drug discovery, development and commercialisation, Syros is located in Cambridge, Mass.

((Comments on this story may be sent to info@m2.com))
COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Apr 8, 2019
Words:836
Previous Article:Tetraphase Pharmaceuticals Presents Preclinical Data on TP-2846, a Novel Drug Candidate for Acute Myeloid Leukemia.
Next Article:Aveo Pharmaceuticals Launches Stock Offering.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters